An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Base rate for an unproven Phase 2 rheumatoid arthritis asset is only moderate, but the study has several supportive design features. It is placebo-controlled in adults with active moderately-to-severe disease, a population with clear room to improve, and it uses established 12-week efficacy readouts: DAS28-hsCRP in Phase 2a and ACR50 in Phase 2b. Those are clinically meaningful endpoints that can detect drug activity in RA if the treatment effect is real. The adaptive Phase 2a/2b structure also helps dose finding before the more decision-relevant Phase 2b portion, which slightly improves the chance of a positive outcome versus a single fixed-dose mid-stage trial. Offsetting that, the provided facts include no mechanism detail or prior human efficacy signal, so typical proof-of-concept risk remains high. Operationally, the estimated primary completion date has passed while the trial is still listed as recruiting, which raises some concern about enrollment or timeline slippage and lowers confidence in a clean, timely disclosure. Overall, I view success as slightly below even odds.

LY3871801 (ocadusertib) is a selective RIPK1 inhibitor licensed from Rigel Pharmaceuticals. The RIPK1 class has an abysmal clinical track record: Sanofi/Denali's oditrasertib failed Phase 2 in ALS, MS, and cutaneous lupus; GSK's GSK2982772 showed no meaningful efficacy in psoriasis or UC; Genentech just dropped flizasertib after Phase 2 futility in AKI (March 2026); Sanofi scrapped its last RIPK1 inhibitor in January 2026. There is zero validated clinical proof-of-concept for RIPK1 inhibition in any autoimmune or inflammatory indication. Phase 1 data for ocadusertib show clean safety and robust target engagement, and preclinical murine models were positive, but this has not translated for any RIPK1 inhibitor to date. The trial still shows 'Recruiting' status despite the estimated primary completion passing 60 days ago, suggesting possible enrollment delays. Lilly already terminated the CNS portion of the Rigel deal. GlobalData cites a 35% Phase 2 RA base rate, but class-wide failures warrant a meaningful downward adjustment.

This is a Phase 2a/2b adaptive study in RA, a competitive therapeutic area with established benchmarks. The endpoints (DAS28-hsCRP and ACR50) are validated and clinically meaningful. Eli Lilly is an experienced sponsor with resources. However, Phase 2 trials carry inherent uncertainty, and the RA landscape has many effective competitors. Adaptive designs offer flexibility but also signal uncertainty. The trial is past primary completion (-60 days), so results are pending. Given typical Phase 2 success rates and competitive RA market, intrinsic YES odds are modestly below even.

The trial is a Phase 2a/2b adaptive design by Eli Lilly, a highly experienced sponsor. The primary endpoints are standard for RA (DAS28-hsCRP change and ACR50). Adaptive designs can increase efficiency, but also introduce complexity in interpretation. The indication is well-understood, but the molecule is novel, and Phase 2 success is not guaranteed despite strong sponsor execution. The trial is still recruiting, so data is not yet available, adding uncertainty. Overall, sponsor quality and standard endpoints provide a slight edge, but the intrinsic probability is only modestly above 50% given the early phase and lack of prior efficacy data for this specific compound.

Adaptive Phase 2a/2b design allows dose optimization from 2a to 2b, efficient for RA. Patient population is standard: active moderate-to-severe RA adults. Phase 2a endpoint (ΔDAS28-hsCRP at 12 weeks) is continuous, sensitive, and well-powered for early efficacy signals. Phase 2b (ACR50 at 12 weeks) is ambitious—ACR50 typically assessed at 24 weeks, and 12-week response rates lower for DMARDs as peak effects lag. Sponsor Eli Lilly excels in RA execution (e.g., baricitinib success). No prior RA data for LY3871801 noted, suggesting novel mechanism with unproven translation risk. Recruiting status despite -60 days past estimated primary completion indicates enrollment delays, elevating operational risk. Disclosure risk minimal post-topline. RA Phase 2 historical success ~25% for binary endpoints; adjusted up slightly for sponsor/adaptive design but tempered by short timeline/stringent 2b bar yields 38% YES odds.

This Phase 2a/2b adaptive study for LY3871801 in RA benefits from Eli Lilly's strong track record in immunology, suggesting competent operational execution. The adaptive design allows for mid-trial modifications based on interim data, statistically increasing the likelihood of a positive readout compared to fixed designs. The primary endpoints are well-established and regulatory-aligned: DAS28-hsCRP is a sensitive, validated measure for Phase 2a, while ACR50 for Phase 2b is a robust efficacy standard. However, the novel mechanism of action for LY3871801 carries inherent target validation risk typical of mid-stage development. The indication, moderately-to-severe RA, is a competitive landscape with high efficacy bars set by existing biologics. While the sponsor's capabilities and adaptive design mitigate some risks, the novel intervention keeps confidence moderate. Overall, the probability of positive results is slightly favored.

LY3871801 is a novel IL-17A/F dual inhibitor from Eli Lilly, a top-tier RA developer with proven execution. Phase 2a/2b adaptive design with DAS28-hsCRP and ACR50 endpoints at 12 weeks are well-validated, reducing measurement risk. The trial completed primary completion 60 days ago with status still 'Recruiting'—suggesting data lock may be pending rather than negative. Lilly's track record in immunology (Taltz success) and the unmet need for oral/ differentiated MOA therapies support positive readout likelihood. No safety flags disclosed. Disclosure risk is moderate given typical 2-4 month lag from completion to results announcement. Endpoint achievability is reasonable based on competitor IL-17 data in RA.

Ocadusertib (LY3871801) is a RIPK1 inhibitor currently in a Phase 2a/2b trial for rheumatoid arthritis (RA). The historical precedent for this drug class in RA is very poor: GSK's selective RIPK1 inhibitor (GSK2982772) failed to demonstrate any meaningful clinical benefit over placebo in a Phase 2 RA study despite achieving its target. While Lilly's compound might possess an optimized pharmacokinetic profile or superior sustained target engagement, the broader RIPK1 inhibitor class has consistently struggled to translate preclinical promise into human clinical efficacy for peripheral autoimmune diseases. Notably, Lilly also terminated the central nervous system (CNS) portion of its RIPK1 collaboration with Rigel in late 2025, signaling broader platform risks. RA remains a difficult indication with a high hurdle for novel non-biologic mechanisms to show competitive efficacy. Given these factors, the intrinsic probability of a positive Phase 2 result is substantially lower than the market suggests.

The trial is a Phase 2 study evaluating the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis. The primary endpoint includes change from baseline in Disease Activity Score and percentage of participants achieving American College of Rheumatology (ACR)50. Given the phase and the specific endpoints, there's a reasonable expectation of positive results if the drug shows a significant improvement over placebo. The study's design and focus on a specific population with a clear primary endpoint contribute to a moderately high confidence in a positive outcome.